RV

Revathy Vikramanthampy Santha

Active Director Director DIN 11268691
DIN 11268691 First appointment Aug 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Revathy Vikramanthampy Santha

Data last updated:

Revathy Vikramanthampy Santha is a Director at Bolshoye Spasibo Pharmaceuticals Private Limited (since 2025). The company operates in Pharma.

DIN 11268691
Primary Designation Director
Industry Pharma
First Appointment 29 Aug 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director29 Aug 20252025Active

Board colleagues of Revathy Vikramanthampy Santha

Directorship timeline

Open interactive timeline →
Bolshoye Spasibo Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Revathy Vikramanthampy Santha

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Revathy Vikramanthampy Santha

Revathy Vikramanthampy Santha currently holds 1 directorship: Bolshoye Spasibo Pharmaceuticals Private Limited (Director, since 29 Aug 2025).

Revathy Vikramanthampy Santha was first appointed on 29 Aug 2025 as Director at Bolshoye Spasibo Pharmaceuticals Private Limited.

The current boards of Revathy Vikramanthampy Santha's companies include Akhil Anilkumar (Bolshoye Spasibo Pharmaceuticals Private Limited), Asha Anil (Bolshoye Spasibo Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available